Zynerba Pharmaceuticals (ZYNE) Gets a Hold Rating from Needham

In a report released today, Serge Belanger from Needham maintained a Hold rating on Zynerba Pharmaceuticals (ZYNEResearch Report). The company’s shares closed last Wednesday at $2.69.

According to TipRanks.com, Belanger is a 3-star analyst with an average return of 1.9% and a 41.7% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical.

Currently, the analyst consensus on Zynerba Pharmaceuticals is a Moderate Buy with an average price target of $9.00.

See today’s best-performing stocks on TipRanks >>

Zynerba Pharmaceuticals’ market cap is currently $121.6M and has a P/E ratio of -2.84.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It engages in the development and commercialization of transdermal pharmaceutically-produced cannabinoid treatments for rare and near-rare neurological and psychiatric, or neuropsychiatric, disorders in patients with high unmet medical needs. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.

Read More on ZYNE: